Pyridyl amides as potent inhibitors of T-type calcium channels

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 6, 2011, Pages 1692-1696

  Reger, Thomas S ^a   Yang, Zhi Qiang ^a   Schlegel, Kelly Ann S ^a   Shu, Youheng ^a   Mattern, Christa ^a   Cube, Rowena ^a   Rittle, Kenneth E ^a   McGaughey, Georgia B ^a   Hartman, George D ^a   Tang, Cuyue ^a   Ballard, Jeanine ^a   Kuo, Yuhsin ^a   Prueksaritanont, Thomayant ^a   Nuss, Cindy E ^a   Doran, Scott M ^a   Fox, Steven V ^a   Garson, Susan L ^a   Li, Yuxing ^a   Kraus, Richard L ^a   Uebele, Victor N ^a   Renger, John J ^a   Barrow, James C ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Electrocorticogram; Epilepsy; Pregnane X receptor; Structure activity relationships; T type calcium channel

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; PIPERIDINE; PYRIDYLAMIDE DERIVATIVE; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; EPILEPSY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; SLEEP;

AMIDES; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; MICE; RATS; RATS, WISTAR;

RODENTIA;

EID: 79952362824     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.01.089     Document Type: Article

References (54)

1. G.W. Zamponi Voltage-Gated Calcium Channels 2005 Kluwer Academic/Plenum
2. R.W. Tsien, and D.B. Wheeler Voltage-Gated Calcium Channels E. Carafoli, C. Klee, Calcium as a Cellular Regulator 1999 Oxford University Press 171 199
3. E.A. Ertel, K.P. Campbell, M.M. Harpold, F. Hofmann, Y. Mori, E. Perez-Reyes, A. Schwartz, T.P. Snutch, T. Tanabe, L. Birnbaumer, R.W. Tsien, and W.A. Catterall Neuron 25 2000 533
4. E. Perez-Reyes Physiol. Rev. 83 2003 117
5. W.A. Catterall, E. Perez-Reyes, T.P. Snutch, and J. Striessnig Pharmacol. Rev. 57 2005 411
6. E.M. Talley, L.L. Cribbs, J.H. Lee, A. Daud, E. Perez-Reyes, and D.A. Bayliss J. Neurosci. 19 1999 1895
7. G.W. Zamponi, R.J. Lewis, S.M. Todorovic, S.P. Arneric, and T.P. Snutch Brain Res. Rev. 60 2009 84
8. M. Steriade, D.A. McCormick, and T.J. Sejnowski Science 262 1993 679
9. M.C. Iftinca, and G.W. Zamponi Trends Pharmacol. Sci. 30 2009 32
10. V. Crunelli, D.W. Cope, and S.W. Hughes Cell Calcium 40 2006 175
11. D. Varela, H. Khosravani, S.E. Heron, C. Bladen, T.C. Williams, M. Newman, S.F. Berkovic, I.E. Scheffer, J.C. Mulley, and G.W. Zamponi Biophys. J. 2007 601
12. A.I. Tröster, S.P. Woods, J.A. Fields, K.E. Lyons, R. Pahwa, and C.I. Higginson Eur. J. Neurol. 9 2002 143
13. R.R. Llinas, and M. Steriade J. Neurophysiol. 95 2006 3297
14. Zhang, Y.; Llinas, R. R.; Lisman, J. E. Front. Neural Circuits 2009, 3. doi: 10.3389/neuro.04.020.2009.
15. S.M. Todorovic, and V. Jevtovic-Todorovic CNS Neurol. Disord.: Drug Targets 5 2006 639
16. P. Lory, and J. Chemin Expert Opin. Ther. Targets 11 2007 717
17. J.P. Clozel, S.I. Ertel, and E.A. Ertel J. Hypertens. 15 1997 S17
18. B.M. Massie Am. J. Cardiol. 80 1997 23I
19. S. Moosmang, N. Haider, B. Bruderl, A. Welling, and F. Hofmann Circ. Res. 98 2006 105
20. M.E. Mullins, B.Z. Horowitz, D.H.J. Linden, G.W. Smith, R.L. Norton, and J. Stump J. Am. Med. Assoc. 280 1998 157
21. D. Kim, I. Song, S. Keum, T. Lee, M.J. Jeong, S.S. Kim, M.W. McEnery, and H.S. Shin Neuron 31 2001 3
22. J. Lee, D. Kim, and H.S. Shin Proc. Natl. Acad. Sci. U.S.A. 101 2004 18195
23. E. Bourinet, A. Alloui, A. Monteil, C. Barrére, B. Couette, O. Poirot, A. Pages, J. McRory, T.P. Snutch, A. Eschalier, and J. Nargeot EMBO J. 24 2005 315
24. H.K. Jung, M.R. Doddareddy, J.H. Cha, H. Rhim, Y.S. Cho, H.Y. Koh, B.Y. Jung, and A.N. Pae Bioorg. Med. Chem. 12 2004 3965
25. W.F. McCalmont, T.N. Heady, J.R. Patterson, M.A. Lindenmuth, D.M. Haverstick, L.S. Gray, and T.L. Macdonald Bioorg. Med. Chem. Lett. 14 2004 3691
26. I.W. Ku, S. Cho, M.R. Doddareddy, M.S. Jang, G. Keum, J.H. Lee, B.Y. Chung, Y. Kim, H. Rhim, and S.B. Kang Bioorg. Med. Chem. Lett. 16 2006 5244
27. M.R. Doddareddy, H. Choo, Y.S. Cho, H. Rhim, H.Y. Koh, J.H. Lee, S.W. Jeong, and A.N. Pae Bioorg. Med. Chem. 15 2007 1091
28. H.N. Seo, J.Y. Choi, Y.J. Choe, Y. Kim, H. Rhim, S.H. Lee, J. Kim, D.J. Joo, and J.Y. Lee Bioorg. Med. Chem. Lett. 17 2007 5740
29. J.J. Hangeland, D.L. Cheney, T.J. Friends, S. Swartz, P.C. Levesque, A.J. Rich, L. Sun, T.R. Bridal, L.P. Adam, D.E. Normandin, N. Murugesan, and W.R. Ewing Bioorg. Med. Chem. Lett. 18 2008 474
30. S.J. Gu, J.K. Lee, A.N. Pae, H.J. Chung, H. Rhim, S.Y. Han, S.J. Min, and Y.S. Cho Bioorg. Med. Chem. Lett. 20 2010 2705
31. W.D. Shipe, J.C. Barrow, Z.Q. Yang, C.W. Lindsley, F.V. Yang, K.S. Schlegel, Y. Shu, K.E. Rittle, M.G. Bock, G.D. Hartman, C. Tang, J.E. Ballard, Y. Kuo, E.D. Adarayan, T. Prueksaritanont, M.M. Zrada, V.N. Uebele, C.E. Nuss, T.M. Connolly, S.M. Doran, S.V. Fox, R.L. Kraus, M.J. Marino, V.K. Graufelds, H.M. Vargas, P.B. Bunting, M. Hasbun-Manning, R.M. Evans, K.S. Koblan, and J.J. Renger J. Med. Chem. 51 2008 3692
32. Z.Q. Yang, J.C. Barrow, W.D. Shipe, K.S. Schlegel, Y. Shu, F.V. Yang, C.W. Lindsley, K.E. Rittle, M.G. Bock, G.D. Hartman, V.N. Uebele, C.E. Nuss, S.V. Fox, R.L. Kraus, S.M. Doran, T.M. Connolly, C. Tang, J.E. Ballard, Y. Kuo, E.D. Adarayan, T. Prueksaritanont, M.M. Zrada, M.J. Marino, V.K. Graufelds, A.G. DiLella, I.J. Reynolds, H.M. Vargas, P.B. Bunting, R.F. Woltmann, M.M. Magee, K.S. Koblan, and J.J. Renger J. Med. Chem. 51 2008 6471
33. J.C. Barrow, K.E. Rittle, T.S. Reger, Z.Q. Yang, P. Bondiskey, G.B. McGaughey, M.G. Bock, G.D. Hartman, C. Tang, J. Ballard, Y. Kuo, T. Prueksaritanont, C.E. Nuss, S.M. Doran, S.V. Fox, S.L. Garson, R.L. Kraus, Y. Li, M.J. Marino, V.K. Graufelds, V.N. Uebele, and J.J. Renger ACS Med. Chem. Lett. 1 2010 75
34. V.N. Uebele, C.E. Nuss, S.V. Fox, S.L. Garson, R. Cristescu, S.M. Doran, R.L. Kraus, V.P. Santarelli, Y. Li, J.C. Barrow, Z.Q. Yang, K.S. Schlegel, K.E. Rittle, T.S. Reger, R.A. Bednar, W. Lemaire, F.A. Mullen, J.E. Ballard, C. Tang, G. Dai, O.B. McManus, K.S. Koblan, and J.J. Renger Cell Biochem. Biophys. 55 2009 81
35. The TTA-Ax nomenclature is provided for consistency across publications, such as Refs. 18 and 19.
36. Due to its potency, favorable physical properties, and ease of preparation compound 15 was labeled with tritium and demonstrated to be an effective radioligand for binding assays. See Ref. 19 for more details.
37. J.H. Hochman, M. Yamazaki, T. Ohe, and J.H. Lin Curr. Drug Metab. 3 2002 257
38. J.H. Lin, and M. Yamazaki Drug Metab. Rev. 23 2003 417
39. A.M.L. Coenen, W.H.I.M. Drinkenburg, M. Inoue, and E.L.J.M. Vanluijtelaar Epilepsy Res. 12 1992 75
40. Y.D. Gao, S.H. Olson, J.M. Balkovec, Y. Zhu, I. Royo, J. Yabut, R. Evers, E.Y. Tan, D.P. Hartley, and R.T. Moseley Xenobiotica 37 2007 124
41. G. Bertilsson, J. Heidrich, K. Svensson, M. Asman, L. Jendeberg, M. Sydow-Backman, R. Ohlsson, H. Postlind, P. Blomquist, and A. Berkenstam Proc. Natl. Acad. Sci. U.S.A. 95 1998 12208
42. R.L. Kraus, Y. Li, Y. Gregan, A.L. Gotter, V.N. Uebele, S.V. Fox, S.M. Doran, J.C. Barrow, Z.-Q. Yang, T.S. Reger, K.S. Koblan, and J.J. Renger J. Pharmacol. Exp. Ther. 335 2010 409
43. 50 values of >30 μM at -80 mV. See Ref. 26 for details.
44. For a partial list of assays, see: V.N. Uebele, A.L. Gotter, C.E. Nuss, R.L. Kraus, S.M. Doran, S.L. Garson, D.R. Reiss, Y. Li, J.C. Barrow, T.S. Reger, Z.Q. Yang, J.E. Ballard, C. Tang, J.M. Metzger, S.P. Wang, K.S. Koblan, and J.J. Renger J. Clin. Invest. 119 2009 1659
45. R.R. Llinás, U. Ribary, D. Jeanmonod, E. Kronberg, and P.P. Mitra Proc. Natl. Acad. Sci. U.S.A. 96 1999 15222
46. D. Contreras CNS Neurol. Disord.: Drug Targets 5 2006 571
47. C. Deleuze, and J.R. Huguenard J. Neurosci. 26 2006 8633
48. We have previously reported that the effects of 37 on active wake in rat are dose-dependent when the compound is dosed during the active phase. See Ref. 28 for details.
49. Compound 37 (TTA-A2) and quinazolinone 2 (TTA-Q6) are both state-dependent T-type channel blockers while piperidine 1 (TTA-P2) is a state-independent blocker. The consistent effect of all three compounds on sleep and wake in rodents suggests that binding to the inactivated state of the channel is sufficient for pharmacological effects.
50. For a discussion on the diastereoselectivity of Grignard additions to chiral 2-pyridyl tert-butyl (Ellman) sulfinimines, see: Kuduk, S. D.; DiPardo, R. M.; Chang, R. K.; Ng, C.; Bock, M. G. Tetrahedron Lett. 2004, 45, 6641-6643.
51. The absolute stereochemistry of a closely related analog of 43 was firmly established by X-ray crystallographic analysis. See Supplementary data for details.
52. The synthesis of 4-cyclopropylphenylacetic acid is described in the Supplementary data. For a leading reference on the use of cyclopropylboronic acid in Suzuki cross-coupling reactions, see: Wallace, D. J.; Chen, C. Y. Tetrahedron Lett. 2002, 43, 6987-6990.
53. We have recently reported that 37 inhibits high-fat diet-induced weight gain in mice. See Ref. 28 for details.
54. The further optimization of 37 into a clinical candidate is described here: Z.-Q. Yang, K.S. Schlegel, Y. Shu, T.S. Reger, R. Cube, C. Mattern, P.J. Coleman, J. Small, G.D. Hartman, J. Ballard, C. Tang, Y. Kuo, T. Prueksaritanont, C.E. Nuss, S. Doran, S.V. Fox, S.L. Garson, Y. Li, R.L. Kraus, V.N. Uebele, A.B. Taylor, W. Zeng, W. Fang, C. Chavez-Eng, M.D. Troyer, J.A. Luk, T. Laethem, W.O. Cook, J.J. Renger, and J.C. Barrow ACS Med. Chem. Lett. 1 2010 504